CP 226269

CP 226269 is a potent dopamine D4 receptor agonist that induces calcium flux with EC50 of 32 nM. CP 226269 stimulates phospholipid methylation (PLM) in SK-N-MC neuroblastoma cells with an EC50 of 2.9 nM. CP 226269 can be used in the research of schizophrenia and other related diseases[1][2][3].

Product Specifications

CAS Number

[220941-93-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cp-226269.html

Purity

99.65

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC1=CC2=C(C=C1)NC(CN3CCN(CC3)C4=NC=CC=C4)=C2

Molecular Formula

C18H19FN4

Molecular Weight

310.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Robert B Moreland, et al. Comparative pharmacology of human dopamine D (2) -like receptor stable cell lines coupled to calcium flux through Galpha (qo5) . Biochem Pharmacol. 2004 Aug 15;68 (4) :761-72. |[2]Sharma A, et al. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol Psychiatry. 1999 May;4 (3) :235-46. |[3]Zhang K, et al. Role of dopamine D (4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions in rats. Neuropsychopharmacology. 2001 Nov;25 (5) :624-32.